Abstract
Sixteen patients with stage IV melanoma,who were heavily pretreated, received11 mg/m2/day of intravenous Irofulvenfor five consecutive days every 28 days.There were no objective tumor responses,although one patient exhibited stabledisease after 4 cycles. The most commontoxicities were grade 1/2 nausea, vomiting,fatigue, anemia, and thrombocytopenia. Onepatient required a dose reduction for anelevated creatinine while another patientrequired cessation of treatment because ofacute ataxia that may have been related toIrofulven. Based upon these data, Irofulvendoes not demonstrate significant antitumoractivity to warrant further investigationin advanced melanoma.
Similar content being viewed by others
References
Houghton AN, Legha S, Bajorin DF: Chemotherapy for metastatic melanoma. In: Balch CM, Houghton AN, Milton GW, et al (eds) Cutaneous Melanoma. JB. Lippincott CO, Philadelphia, 1992, p. 499
Hill GJ Jr., Krementz ET, Hill HZ: Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group Protocols 7130, 7131, and 7131A). Cancer 53(6): 1299–305, 1984
Legha SS: Current therapy for malignant melanoma. Semin Oncol 16(1, Suppl 1): 34–44, 1989
Sparano JA, Fisher RI, Sunderland M, Margolin K, Ernest ML, Sznol M, Atkins MB, Dutcher JP, Micetich KC, Weiss GR: Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. J Clin Oncol 11(10): 1969–1977, 1993
Demchak PA, Mier JW, Robert NJ, O'Brien K, Gould JA, Atkins MB: Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma: a pilot study. J Clin Oncol 9(10): 1821–1830, 1991
Flaherty LE, Robinson W, Redman BG, Gonzalez R, Martino S, Kraut M, Valdivieso M, Rudolph AR: A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanoma. Cancer 71(11): 3520–3525, 1993
Atkins MB, O'Boyle KR, Sosman JA, Weiss GR, Margolin KA, Ernest ML, Kappler K, Mier J, Sparano JA, Fischer RI: Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. J Clin Oncol 12(8): 1553–1560, 1994
Kelner MJ, McMorris TC, Estes L: Characterization of illudin S sensitivity in DNA repair-deficient Chinese hamster cells: Unusually high sensitivity in ERCC2 and ERCC3 DNA helicase-deficient mutants compared to other chemotherapeutic agents. Biochem Pharmacol 48: 403–409, 1994
Izbicka E, Davidson K, Von Hoff DD: MGI-114 antiproliferative effects against human tumor cell lines with different p53 and p21waf expression. Anticancer Res 19: 1299–1308, 1999
Kelner MJ, McMorris TC, Taetle R: Preclinical evaluation of illudins as anticancer agents: Basis for selective cytotoxicity. J Natl Cancer Inst 82: 1562–1565, 1990
Kelner MJ, McMorris TC, Taetle R: In vitro and in vivo studies on the anticancer activity of dehydroilludin M. Anticancer Res 15: 873–878, 1995
Eckhardt SG, Baker SD, Britten CD, Hidalgo M, Siu L, Hammond LA, Villalona-Calero MA, Felton S, Drengler R, Kuhn JG, Clark GM, Smith SL, MacDonald JR, Smith C, Moczygemba J, Weitman S, Von Hoff DD, Rowinsky EK: Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies. J Clin Oncol 18(24): 4086–4097, 2000
Sato Y, Kashimoto S, MacDonald JR, Nakona K: In vivo activity of MGI 114 (6-hydroxymethylacylfulvene, HMAF) in various human tumor xenograft models including several lung and gastric tumors. Eur J Canc 37(11): 1419–28, 2001
Simon R: Clinical Trials. In: DeVita VT, Hellman S, and Rosenberg SA (eds) Cancer: Principles and Practice of Oncology 6th edition.: Lippincott, Williams, and Wilkins Publishers, Philadelphia, 2001, pp 521–538
Casper ES, Bajorin D: Phase II trial of carboplatin in patients with advanced melanoma. Investigational New Drugs 8(2): 187–90, 1990
Verma S, Quirt IC, Eisenhauer EA, Iscos NA, Young VJ, Bodurtha AJ, Davidson J: A phase II trial of weekly edatrexate (10-EDAM) in metastatic melanoma: A National Cancer Institute of Canada Clinical Trials Group Study. Ann Oncol 4(3): 254–5, 1993
Sessa C, Aamdal S, Wolff I, Eppelbaum R, Smyth JF, Sulkes A, ten Bokkel Huinin KW, Vermorken J, Wanders J, Franklin H: Gemcitabine in patients with advanced malignant melanoma or gastric cancer: Phase II studies of the EORTC Early Clinical Trial Group. Ann Oncol 5(5): 471–2, 1994
Aamdal S, Bruntsch U, Kerger J, Verweij J, ten Bokkel Huinin KW, Wanders J, Rastogi R, Franklin HR, Kaye SB: Zeniplatin in advanced malignant melanoma and renal cancer: Phase II studies with unexpected nephrotoxicity. Cancer Chemother Pharmacol 40(5): 439–43, 1997
Ellerhorst JA, Bedikian A, Ring S, Buzaid AC, Eton O, Legha SS: Phase II trial of doxil for patients with metastatic melanoma refractory to front line therapy. Oncol Rep 6(5): 1097–9, 1999
Gonzalez R, Ebbinghaus S, Henthorn TK, Miller D, Kraft AS: Treatment of patients with metastatic melanoma with bryostatin-a phase II study. Melanoma Res 9(6): 599–606, 1999
Weitman S, Barrera H, Moore R, Gonzalez C, Marty J, Hilsenbeck S, MacDonald JR, Waters SJ, Von Hoff DD: MGI-114: augmentation of antitumor activity when combined with topetecan. J Ped Hematol Oncol 22(4): 306–14, 2000
Hammond LA, Hilsenbeck SG, Eckhardt SG, Marty J, Mangold G, MacDonald JR, Rowinsky EK, Von Hoff DD, Weitman S: Enhanced antitumour activity of 6-hydroxymethylacylfulvene in combination with topetecan or paclitaxel in the MV522 lung carcinoma xenograft model. Eur J Canc 36(18): 2430–6, 2000
Kelner MJ, McMorris TC, Estes L, Samson KM, Trani NA, MacDonald JR: Anti-leukemic action of the novel agent MGI-114 (HMAF) and synergistic action with topetecan. Leukemia 14(1): 136–41, 2000
Britten CD, Hilsenbeck SG, Eckhardt SG, Marty J, Mangold S, MacDonald JR, Rowinksky EK, Von Hoff DD, Weitman S: Enhanced activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model. Cancer Res 59(5): 1049–53, 1999
Kraut EH, Walker MJ, Staubus A, Gochnour D, Balcerzak SP: Phase II trial of topotecan in malignant melanoma. Cancer Invest 15(4): 318–20, 1997